← United States · Coverage record
US · SEC FORM 4
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Nasdaq · CIK 0001595097 · Healthcare · Biotechnology
INSIDER SIGNAL
3 qualifying P purchase groups
in the current 180-day scoring window
17 Form 4 transaction lines observed in the same window
6 sales · 8 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.
Purchase breadth & concentration
Roles in the peak window: Chief Business Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-08-11 · Saxena Nishant C.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 3,054,964
- Previous report
- 2,759,255
- Avg daily volume
- 791,386
- Days to cover
- 3.9
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 2,600 | USD 9.63 | USD 25,038 | SEC filing ↗ |
| 2026-06-03 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 9,000 | USD 7.58 | USD 68,220 | SEC filing ↗ |
| 2026-06-02 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 4,500 | USD 7.33 | USD 32,985 | SEC filing ↗ |
| 2024-09-20 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | Purchase (P) | Common Stock | 350,000 | USD 20.01 | USD 7,004,060 | SEC filing ↗ |
| 2024-03-08 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | Purchase (P) | Common Stock | 300,000 | USD 44.38 | USD 13,314,193 | SEC filing ↗ |
| 2024-03-07 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | Purchase (P) | Common Stock | 250,000 | USD 40.05 | USD 10,013,367 | SEC filing ↗ |
| 2024-02-02 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | Purchase (P) | Common Stock | 750,000 | USD 19.00 | USD 14,250,000 | SEC filing ↗ |
| 2024-01-26 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | Purchase (P) | Common Stock | 282,632 | USD 32.24 | USD 9,111,941 | SEC filing ↗ |
| 2022-08-10 | Millian Craig Stuart | Purchase (P) | Common Stock | 5,000 | USD 0.25 | USD 1,250 | SEC filing ↗ |
| 2022-08-10 | Cohen Yuval | Purchase (P) | Common Stock | 3,800 | USD 0.26 | USD 988 | SEC filing ↗ |
| 2022-08-10 | Moran Sean F. | Purchase (P) | Common Stock | 20,000 | USD 0.26 | USD 5,200 | SEC filing ↗ |
| 2022-05-16 | Moran Sean F. | Purchase (P) | Common Stock | 12,000 | USD 0.30 | USD 3,600 | SEC filing ↗ |
| 2022-05-16 | Cohen Yuval | Purchase (P) | Common Stock | 10,500 | USD 0.25 | USD 2,625 | SEC filing ↗ |
| 2022-03-10 | Millian Craig Stuart | Purchase (P) | Common Stock | 10,000 | USD 0.37 | USD 3,700 | SEC filing ↗ |
| 2022-03-10 | Moran Sean F. | Purchase (P) | Common Stock | 15,000 | USD 0.37 | USD 5,550 | SEC filing ↗ |
Form 4 evidence
36 transaction lines in the latest 365-day window; 138 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Ben Yong | Sale (S) | Common Stock, par value $0.0001 per share | 2,000 | USD 7.84 | USD 15,680 | SEC filing ↗ |
| 2026-08-16 | Nicacio Leonardo Viana | Award / grant (A) | Common Stock, par value $0.0001 per share | 58,333 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-11 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 2,600 | USD 9.63 | USD 25,038 | SEC filing ↗ |
Show recent Form 4 evidence (30 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Ben Yong | Sale (S) | Common Stock, par value $0.0001 per share | 2,000 | USD 7.84 | USD 15,680 | SEC filing ↗ |
| 2026-08-16 | Nicacio Leonardo Viana | Award / grant (A) | Common Stock, par value $0.0001 per share | 58,333 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-08-11 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 2,600 | USD 9.63 | USD 25,038 | SEC filing ↗ |
| 2026-08-07 | Moran Sean F. | Sale (S) | Common Stock, par value $0.0001 per share | 12,000 | USD 10.08 | USD 120,960 | SEC filing ↗ |
| 2026-08-07 | Cohen Yuval | Sale (S) | Common Stock, par value $0.0001 per share | 17,000 | USD 10.08 | USD 171,360 | SEC filing ↗ |
| 2026-06-10 | Kung Winston | Sale (S) | Common Stock, par value $0.0001 per share | 2,026 | USD 7.91 | USD 16,026 | SEC filing ↗ |
| 2026-06-10 | Jenkins John Kenneth | Sale (S) | Common Stock, par value $0.0001 per share | 4,800 | USD 7.91 | USD 37,968 | SEC filing ↗ |
| 2026-06-10 | Altmeyer Anne | Sale (S) | Common Stock, par value $0.0001 per share | 2,412 | USD 7.91 | USD 19,079 | SEC filing ↗ |
| 2026-06-03 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 9,000 | USD 7.58 | USD 68,220 | SEC filing ↗ |
| 2026-06-02 | Saxena Nishant C | Purchase (P) | Common Stock, par value $0.0001 per share | 4,500 | USD 7.33 | USD 32,985 | SEC filing ↗ |
| 2026-05-21 | Saxena Nishant C | Award / grant (A) | Common Stock, par value $0.0001 per share | 58,300 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-19 | Pfeiffenberger Brent | Award / grant (A) | Common Stock, par value $0.0001 per share | 7,500 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-19 | Kung Winston | Award / grant (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-19 | Jenkins John Kenneth | Award / grant (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-19 | Jacques Rachelle Suzanne | Award / grant (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-19 | Ben Yong | Award / grant (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-05-19 | Altmeyer Anne | Award / grant (A) | Common Stock, par value $0.0001 per share | 3,800 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-02 | Smethurst Dominic | Sale (S) | Common Stock, par value $0.0001 per share | 6,097 | USD 8.30 | USD 50,605 | SEC filing ↗ |
| 2026-02-17 | Hodgson Ian | Sale (S) | Common Stock, par value $0.0001 per share | 847 | USD 7.38 | USD 6,251 | SEC filing ↗ |
| 2026-02-13 | Moran Sean F. | Sale (S) | Common Stock, par value $0.0001 per share | 4,701 | USD 7.78 | USD 36,574 | SEC filing ↗ |
| 2026-02-13 | Cohen Yuval | Sale (S) | Common Stock, par value $0.0001 per share | 13,871 | USD 7.78 | USD 107,916 | SEC filing ↗ |
| 2026-02-03 | Smethurst Dominic | Sale (S) | Common Stock, par value $0.0001 per share | 3,285 | USD 8.09 | USD 26,576 | SEC filing ↗ |
| 2026-02-03 | Hodgson Ian | Sale (S) | Common Stock, par value $0.0001 per share | 2,415 | USD 8.09 | USD 19,537 | SEC filing ↗ |
| 2026-01-14 | Smethurst Dominic | Award / grant (A) | Common Stock, par value $0.0001 per share | 28,365 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-14 | Moran Sean F. | Award / grant (A) | Common Stock, par value $0.0001 per share | 28,082 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-14 | Hodgson Ian | Award / grant (A) | Common Stock, par value $0.0001 per share | 28,365 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-14 | Cohen Yuval | Award / grant (A) | Common Stock, par value $0.0001 per share | 50,000 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-11 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP | Sale (S) | Common Stock | 30,029 | USD 11.46 | USD 344,132 | SEC filing ↗ |
| 2025-10-27 | Cohen Yuval | Sale (S) | Common Stock, par value $0.0001 per share | 8,973 | USD 17.14 | USD 153,797 | SEC filing ↗ |
| 2025-10-27 | Cohen Yuval | Option exercise / conversion (M) | Common Stock, par value $0.0001 per share | 8,973 | USD 4.26 | USD 38,225 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | CRBP |
| CIK | 0001595097 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 138 transaction lines from 2020-03-17 to 2026-09-14 47 P purchase lines · 37 S sale lines · 54 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.